AI in gastroenterology is evolving from standalone tools to real-time, cloud-connected intelligence embedded directly into procedures. Odin Vision, now part of Olympus, is building AI systems that integrate into live endoscopy workflows—analyzing video streams in real time and overlaying insights to help clinicians detect and characterize polyps during colonoscopy. The core value is immediate:👉 Addressing a known gap where a significant share of precancerous polyps are still missed during procedures But the bigger shift is architectural. Instead of on-site hardware, these systems run on cloud-based infrastructure, enabling: This transforms AI from a point solution into a connected layer across endoscopy…
Author: Abhay Panchal
AI is no longer experimental in healthcare—it’s becoming part of the daily workflow, with adoption now reaching a clear tipping point. According to Doximity’s report, 94% of physicians are using or interested in AI, and more than half are already using it in clinical practice. Notably, gastroenterology is among the top-adopting specialties, signaling how quickly AI is embedding into GI workflows. But the real story isn’t clinical disruption—it’s operational relief. Today, AI’s primary value lies in reducing administrative burden: This is where physicians are already seeing impact—less after-hours work, improved efficiency, and more time for patients. At the same time,…
Abbott’s acquisition of Exact Sciences isn’t just a portfolio expansion—it’s a strategic pivot toward owning the front end of disease detection. By bringing in Exact Sciences’ cancer screening capabilities (including non-invasive tests like Cologuard), Abbott is moving beyond traditional diagnostics into a model centered on early detection, longitudinal monitoring, and recurring patient engagement. This reflects a broader shift in healthcare economics:👉 The value is moving upstream—from diagnosing disease to identifying it earlier, at scale, and repeatedly. For Abbott, this creates a more integrated diagnostics stack—spanning lab tests, point-of-care tools, and now at-home cancer screening. But it also places the company…
GI surgery is undergoing a fundamental shift—from an art shaped by experience and intuition to a data-driven, digitally quantified discipline. Historically, surgical mastery relied on “gestalt”—the unspoken feel and judgment developed over years of training. But with the rise of AI, robotics, and real-time data layers, that intuition is now being broken down into measurable, teachable components. Technologies like AI-assisted endoscopy, augmented reality interfaces, and remote collaboration tools are doing more than improving detection—they’re decoding surgery itself:
A growing consensus is emerging among obesity experts: the healthcare system—not the therapy—is the biggest bottleneck in obesity care. As GLP-1 demand surges, traditional specialist-led models are breaking down under volume. Referral centers are overwhelmed, prior authorizations are consuming entire teams, and access remains uneven—revealing a system not designed for a disease affecting millions. The proposed shift is clear: move from siloed care to a distributed, multidisciplinary model where primary care, pharmacists, dietitians, and specialists share ownership—similar to how diabetes is managed today. But scaling care isn’t just about access. It’s about coordination: At the same time, a hard truth…
Gastroenterologists face rising clinical and operational obstacles as the GI diseases become more prevalent in the U.S. population and reimbursement rates fall for essential procedures. Here are five studies scaring GIs: 1. Gastrointestinal cancers are expected to double globally by 2050, according to a new multi-institutional study co-led by Los Angeles-based Cedars-Sinai, among others. According to the study, the biggest increases will be in pancreatic cancer diagnoses and colorectal cancer deaths. Ju Dong Yang, MD, a professor and medical director of Cedars-Sinai’s liver cancer program said that up to 70% of liver cancers are preventable. While hepatitis B and C…
Micro-Tech Endoscopy’s acquisition of global distribution rights for key Conmed GI products isn’t just a portfolio expansion—it’s a strategic consolidation of control across the endoscopy value chain. By bringing Duraclip (hemostasis) and Precisor/Optibite (biopsy) fully in-house, Micro-Tech is moving from being a behind-the-scenes manufacturer to a frontline commercial player with a more complete procedural toolkit. The timing is equally telling. Conmed’s exit from the GI segment reflects a broader reality in medtech: fragmented portfolios are giving way to focused, category-dominant players. In contrast, Micro-Tech is doubling down—building an integrated offering that spans closure, biopsy, and visualization. For providers, especially ASCs,…
Olympus’ $1M+ equipment grant to ASGE isn’t just philanthropy—it’s a strategic investment in shaping the next generation of endoscopists and, indirectly, the future of procedural adoption. By equipping ASGE’s training institute with its latest EVIS X1 systems, Olympus is embedding its technology directly into the learning environment of fellows and practicing GIs—where preferences, habits, and platform familiarity are formed early. This highlights a deeper dynamic in GI: as endoscopy becomes more advanced (ERCP, EUS, ESD), the bottleneck is no longer just technology—it’s training, proficiency, and comfort with increasingly sophisticated systems.
A new liquid biopsy platform, cf-EpiTracing, is pushing non-invasive diagnostics beyond detection—into understanding where disease actually comes from. Developed by researchers at Peking University, the technology can extract detailed epigenetic signals from just a drop of blood, enabling tissue-of-origin tracing, disease subtyping, and outcome prediction—a long-standing limitation of traditional liquid biopsies. In colorectal cancer, early results show striking accuracy (over 90% in validation cohorts), pointing toward a future where screening could move upstream—earlier, simpler, and potentially more precise than today’s methods. But the bigger shift is conceptual. Liquid biopsies are evolving from binary “signal detection” tools into multi-dimensional diagnostic platforms,…
The American College of Gastroenterology’s first comprehensive guideline on hepatic encephalopathy (HE) marks a notable shift: from clinician-driven protocols to patient-centered, real-world management of a complex, often underdiagnosed condition. Led by Dr. Jasmohan Bajaj, the guidance challenges long-held clinical habits—most notably the overreliance on ammonia levels—arguing instead for symptom-driven assessment and practical cognitive testing that can actually be implemented in routine care. But the deeper change is philosophical. HE is no longer framed purely as a hepatic complication—it’s positioned as a multidimensional disease affecting cognition, caregivers, and quality of life, requiring involvement beyond the physician.